1. A data acquisition device for an electric motor, the data acquisition device comprising:
a location determining component for determining a location of the motor and generating corresponding location data;
a sensor for sensing a condition of the motor or a component driven by the motor and generating sensor data;
a communication device;
control unit for receiving the location data from the location determining component and the sensor data from the sensor and for instructing the communication device to transmit at least portions of the location data and the sensor data to a remote monitoring device that is located at a different site than the electric motor; and
a power source for powering the location determining component, the sensor, the communication device, and the control unit.
2. The data acquisition device of claim 1, further comprising an input for receiving additional sensor data from a sensor that senses a condition of a device separate from the electric motor or the component driven by the motor, the control unit and the communication device being further operable to transmit at least portions of the additional sensor data to the remote monitoring device.
3. The data acquisition device of claim 1, wherein the location determining component is a global navigation satellite system receiver selected from the group consisting of a GPS, GLONASS, Galileo, and Beidou system receiver.
4. The data acquisition device of claim 1, wherein the sensor is a vibration sensor, a temperature sensor, a current sensor, a voltage sensor, a power sensor, a speed sensor, a pressure sensor, a flow sensor, or a motor flux sensor.
5. The data acquisition device of claim 1, wherein the communication device is a cellular phone transmitter or a peer-to-peer network transmitter.
6. The data acquisition device of claim 1, wherein the control unit includes a processor, integrated circuit, or application specific integrated circuit.
7. The data acquisition device of claim 1, wherein the power source is selected from the group consisting of a current transformer, a power scavenging flux coil, a battery, and a capacitor.
8. The data acquisition device of claim 1, wherein the control unit and the communication device periodically transmit the location data and the sensor data to the remote computing device.
9. The data acquisition device of claim 1, wherein the control unit only transmits the location data and the sensor data if the control unit determines the sensor data deviates from a selected threshold range.
10. The data acquisition device of claim 1, wherein the remote monitoring device is a web server.
11. The data acquisition device of claim 1, wherein the remote monitoring device is a mobile phone.
12. A data acquisition device for an electric motor, the data acquisition device comprising:
an input for communicating with a location determining component that determines a location near the electric motor and generates corresponding location data;
an input for communicating with a sensor that senses a condition of the motor, a component driven by the motor, or a device separate from the electric motor and that generates corresponding sensor data;
an input for communicating with a communication device;
a control unit for receiving the location data from the location determining component and the sensor data from the sensor and for instructing the communication device to transmit at least portions of the location data and the sensor data to a remote monitoring device for remote monitoring purposes; and
an input for receiving power from a power source for powering the control unit.
13. The data acquisition device of claim 12, wherein the power source is a passive power source for scavenging power from the motor.
14. The data acquisition device of claim 13, wherein the passive power source is a power scavenging transformer coil and a battery or a capacitor for storing power from the power scavenging flux coil.
15. The data acquisition device of claim 12, wherein the location determining component is a GNSS receiver selected from the group consisting of a GPS, GLONASS, Galileo and Beidou system receiver.
16. The data acquisition device of claim 12, wherein the sensor is a vibration sensor, a temperature sensor, a current sensor, a voltage sensor, a power sensor, a speed sensor, a pressure sensor, a flow sensor, or a motor flux sensor.
17. The data acquisition device of claim 12, wherein the communication device is a cellular phone transmitter or a peer-to-peer network transmitter.
18. A method for monitoring operation of an electric motor for repair, replacement, or monitoring purposes, the method comprising:
providing a data acquisition device to be attached to or near the electric motor;
receiving data from the data acquisition device at a remote monitoring device that is at a different site than the electric motor, the data including:
a) location data representative of a location of the data acquisition device, and
b) sensor data representative of a condition of the electric motor or a component driven by the electric motor;
analyzing the sensor data at the remote monitoring device; and
sending at least a portion of the sensor data, or data derived from the sensor data, from the remote computer system to another device for monitoring, data collection, maintenance or replacement purposes.
19. The method of claim 18, the data acquisition device comprising:
a location determining component for determining the location data;
a sensor for generating the sensor data;
a communication device;
control unit for receiving the location data and the sensor data from the location determining component and the sensor and for instructing the communication device to transmit the location data and the sensor data to the remote monitoring device; and
a power source for powering the location determining component, the sensor, the communication device, and the control unit.
20. The method of claim 19, further comprising the step of:
sending a notification from the remote monitoring device to a service person if the analysis of the sensor data indicates the motor is in need of service or replacement, the notification including the location of the motor.
21. A data acquisition device for an electric motor, the data acquisition device comprising:
a location determining component for determining a location of the motor and generating corresponding location data;
a communication device;
control unit for receiving the location data from the location determining component and for instructing the communication device to transmit at least portions of the location data to a remote monitoring device that is located at a different site than the electric motor; and
a power source for powering the location determining component, the communication device, and the control unit, wherein the power source is selected from the group consisting of a current transformer, a power scavenging flux coil, a battery, and a capacitor.
22. The data acquisition device of claim 21, further comprising a sensor for sensing a condition of the motor or a component driven by the motor and generating sensor data, wherein the control unit is operable for receiving the sensor data from the sensor and for instructing the communication device to transmit at least a portion of the sensor data along with the location data.
23. A data acquisition device for an electric motor, the data acquisition device comprising:
a location determining component for determining a location of the motor and generating corresponding location data;
a sensor for sensing a condition of the motor or a component driven by the motor and generating sensor data;
a communication device; and
control unit for receiving the location data from the location determining component and the sensor data from the sensor and for instructing the communication device to transmit at least portions of the location data and the sensor data to a remote monitoring device that is located at a different site than the electric motor.
24. The data acquisition device of claim 23, further comprising a power source for powering the location determining component, the sensor, the communication device, and the control unit, wherein the power source is selected from the group consisting of a current transformer, a power scavenging flux coil, a battery, and a capacitor.
25. A data acquisition device for an electric motor, the data acquisition device comprising:
a sensor for sensing a condition of the motor or a component driven by the motor and generating sensor data;
a communication device;
control unit for receiving the sensor data from the sensor and for instructing the communication device to transmit at least portions of the sensor data to a remote monitoring device that is located at a different site than the electric motor; and
a power source for powering the sensor, the communication device, and the control unit wherein the power source is selected from the group consisting of a current transformer, a power scavenging flux coil, a battery, and a capacitor.
26. The data acquisition device of claim 25, further comprising a location determining component for determining a location of the motor and generating corresponding location data, wherein the control unit is operable for receiving the location data from the location determining component and for instructing the communication device to transmit at least a portion of the location data along with the sensor data.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treating progressive multiple sclerosis in a patient comprising administering to the patient an effective amount of an anti-CD20 antibody, wherein treatment is based upon the patient having one or more characteristics selected from the group consisting of (a) an age less than about 55 years, (b) one or more gadolinium staining lesions, (c) at least about a one point increase in Expanded Disability Status Scale (EDSS) over two years prior to starting treatment, and (d) a Multiple Sclerosis Severity Score (MSSS) greater than about 5 points.
2. The method of claim 1, wherein the progressive multiple sclerosis is primary progressive multiple sclerosis.
3. The method of claim 1, wherein the progressive multiple sclerosis is secondary progressive multiple sclerosis.
4. The method of claim 1, wherein the progressive multiple sclerosis is progressive relapsing multiple sclerosis.
5. The method of claim 1, wherein the patient is not diagnosed with relapsing remitting multiple sclerosis when starting treatment.
6. The method of claim 1, wherein the patient further has evidence of inflammation in a sample.
7. The method of claim 6, wherein the sample is a cerebrospinal fluid sample.
8. The method of claim 7, wherein evidence of inflammation is indicated by an elevated IgG index.
9. The method of claim 7, wherein evidence of inflammation is indicated by IgG oligoclonal bands detected by isoelectric focusing.
10. The method of claim 1, wherein the patient has had an EDSS of greater than about 5.0 for less than about 15 years.
11. The method of claim 1, wherein the patient has had an EDSS less than or equal to about 5.0 for less than about 10 years.
12. The method of claim 1, wherein the increase in EDSS over two years prior to starting treatment is not attributable to relapse.
13. The method of claim 1, wherein the increase in EDSS is at least about a 1.5 point increase in EDSS over two years prior to starting treatment.
14. The method of claim 13, wherein the increase in EDSS over two years prior to starting treatment is not attributable to relapse.
15. The method of claim 1, wherein the age of the patient is less than about 51.
16. The method of claim 1, wherein the patient further had two or more relapses within two years prior to starting treatment.
17. The method of claim 1, wherein the EDSS when starting treatment is between about 3.0 and about 6.5.
18. The method of claim 1, wherein the treatment reduces the time to confirmed disease progression.
19. The method of claim 18, wherein confirmed disease progression is an increase in EDSS that is sustained for twelve weeks.
20. The method of claim 18, wherein confirmed disease progression is an increase in EDSS that is sustained for twenty-four weeks.
21. The method of claim 1, wherein the anti-CD20 antibody comprises: a) a heavy chain variable region comprising three CDR regions comprising SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and b) a light chain variable region comprising three CDR regions comprising SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
22. The method of claim 1, wherein the anti-CD20 antibody is ocrelizumab.
23. The method of claim 1, wherein the anti-CD20 antibody is rituximab.
24. The method of claim 1, wherein the anti-CD20 antibody is ofatumumab.
25. The method of claim 1, wherein the anti-CD20 antibody is TRU-015 or SBI-087.
26. The method of claim 1, wherein the anti-CD20 antibody is GA101.
27. The method of claim 1, wherein the anti-CD20 antibody is hA20.
28. The method of claim 1, wherein the effective amount of the anti-CD20 antibody is administered to the patient to provide an initial anti-CD20 antibody exposure of between about 0.3 to about 4.0 grams followed by a second anti-CD20 antibody exposure of between about 0.3 to about 4.0 grams.
29. The method of claim 28, wherein the initial anti-CD20 antibody exposure andor the second anti-CD20 antibody exposure is between about 0.3 to about 1.5 grams.
30. The method of claim 29, wherein the second exposure not being provided until from about 16 to 60 weeks from the initial exposure.
31. The method of claim 30, wherein each of the anti-CD20 antibody exposures is provided to the patient as one or two doses of anti-CD20 antibody.
32. A method of treating progressive multiple sclerosis in a patient provided that the patient has been found to have one or more characteristics selected from the group consisting of (a) an age less than about 55 years, (b) one or more gadolinium staining lesions, (c) at least about a one point increase in Expanded Disability Status Scale (EDSS) over two years prior to starting treatment, and (d) a Multiple Sclerosis Severity Score (MSSS) greater than about 5 points, the treatment comprising administering to the patient an effective amount of an anti-CD20 antibody.
33. A method of treating progressive multiple sclerosis, comprising:
(a) selecting a patient having progressive multiple sclerosis, wherein said patient has one or more characteristics selected from the group consisting of (i) an age less than about 55 years, (ii) one or more gadolinium staining lesions, (iii) at least about a one point increase in Expanded Disability Status Scale (EDSS) over two years prior to starting treatment, and (iv) a Multiple Sclerosis Severity Score (MSSS) greater than about 5 points; and
(b) administering to the patient thus selected an effective amount of an anti-CD20 antibody.
34.-38. (canceled)
39. A method of treating multiple sclerosis in a patient comprising administering an effective amount of ocrelizumab to the patient to provide an initial ocrelizumab exposure of between sf-3117272 about 0.3 to about 0.6 grams followed by a second ocrelizumab exposure of between about 0.3 to about 0.6 grams, the second exposure not being provided until from about 16 to 60 weeks from the initial exposure, and each of the ocrelizumab exposures is provided to the patient as one or two doses of ocrelizumab.
40. The method of claim 39, wherein the initial ocrelizumab exposure comprises a first dose and a second dose of ocrelizumab, wherein the first dose and second dose of ocrelizumab is about 0.3 grams.
41. The method of claim 40, wherein the second ocrelizumab exposure comprises a single dose of ocrelizumab, wherein the single dose of ocrelizumab is 0.6 grams.
42. The method of claim 41, wherein the second ocrelizumab exposure is provided approximately 24 weeks after the initial ocrelizumab exposure.
43. The method of claim 42, further comprising providing a third ocrelizumab exposure.
44. The method of claim 43, further comprising providing a fourth ocrelizumab exposure.
45. The method of claim 44, further comprising providing a fifth ocrelizumab exposure.
46. The method of claim 42, further comprising providing between about one to about three subsequent ocrelizumab exposures.
47. (canceled)